GLP-1 medications are transforming how we think about chronic disease management and, more importantly, prevention. Ongoing research has found them to be effective in the prevention or treatment of diabetes, heart attacks and strokes, kidney disease, liver disease, sleep apnea, and more.
Pfizer said a patient dosed with danuglipron developed potential drug-induced liver injury. Pfizer is stopping further work on this program, a move that comes nearly two years after it discontinued development of a different obesity drug due to liver safety signals in a clinical trial.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
Engaging in data sharing, observational cohort research, and deeper analysis of available data to yield further insights can drive improved results for patients, making label and cohort extension faster and more robust.
CagriSema, a dual-acting drug in development by Novo Nordisk, met the goal of a Phase 3 test in patients with obesity and type 2 diabetes. But the topline results don’t show an advantage over Eli Lilly’s commercialized obesity medication, Zepbound.
For GLP-1 receptor agonists specifically, adherence challenges are a major concern, as these medications require long-term use to achieve meaningful health benefits in chronic conditions like diabetes and obesity.
Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others believe these drugs are dangerous for patients.
Richard Fu details the company's approach to nutrition therapy and strategy for patients using GLP-1s.
Regulators will have their work cut out for them under a new administration that has expressed an anti-regulatory preference. Republicans next year will control the White House, Senate and House. What will it all mean for pharmacy leaders?
Investors showed appetite for Metsera’s IPO, as shares of the clinical-stage metabolic medicines biotech popped 47% in their Nasdaq debut. Maze Therapeutics and Beta Bionics also priced IPOs; the three companies raised $636 million combined.
Verdiva Bio’s once-a-week oral GLP-1 drug is ready for Phase 2 testing. The drug, made with a proprietary technology that enables oral dosing, was licensed from Sciwind Biosciences.
We must think beyond one-size-fits-all solutions and embrace the diversity of obstructive sleep apnea. This means continuing to innovate, collaborating across sectors, and keeping patients at the center of every decision.
How Apella leverages technology to increase OR efficiency.
Leaders from Red Cell Partners, an investment and incubation firm that funds and builds healthcare startups, shared key trends they’re keeping their eyes on this year — including increased adoption of AI agents and redefined GLP-1 management frameworks for employers.
Zocdoc CEO Oliver Kharraz has some predictions about how healthcare will change in 2025 — including the rise of cash-pay services and the potential restructuring of Amazon’s healthcare assets.
Effective diabetes management requires a shift from focusing purely on blood sugar levels and weight management medications to embracing the psychological and biological contributors that drive obesity and the disease.
Amgen’s experimental obesity drug, MariTide, led to an average 20% reduction in weight in a Phase 2 clinical trial. While investors hoped for greater weight loss, some analysts say less burdensome monthly dosing of MariTide could make it competitive against weekly injectable weight drugs Zepbound and Wegovy.
Pricy GLP-1 medications are here to stay — let's focus on turning their potential into lasting, meaningful impact.